US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash.

The purchase consideration for the acquisition will amount to $7.2bn, including the assumption of $2bn of net debt owed by the target company.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The target company is a Netherlands-based contract development and manufacturing organisation.

"Norgine has reached an agreement for the acquisition of Merus Labs International in a cash deal."

Norgine has reached an agreement for the acquisition of Merus Labs International in a cash deal.

The entire issued and outstanding common shares of the target company will be acquired at a price of $1.65 a share, which represents an enterprise value of approximately $342m for Merus Labs.

The acquisition will be financed through existing cash and recently secured credit facilities.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Netherlands-based Norgine specialises in gastroenterology, hepatology, cancer and supportive care, while Canadian firm Merus Labs is a specialist pharmaceutical company focused on oncology, women's health, cardiovascular, urology, infectious diseases.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact